ClinicalTrials.gg
CompletedNCT06030193NightingaleUpdated Apr 3, 2026

Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)

A Phase 2 interventional study of QLS-111 ophthalmic solution (0.015%) and Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) in Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral and Low-Tension Glaucoma, Unspecified Eye, sponsored by Qlaris Bio, Inc.. Completed at 1 site in South Korea. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Qlaris Bio, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.

Read the detailed description

A randomized, active-controlled, multi-site, double-masked, pilot study to evaluate the safety and tolerability of QLS-111 0.015% versus Timolol maleate ophthalmic preservative free (PF) 0.5% ophthalmic solution in subjects with NTG. Primary objective is to evaluate the ocular and systemic safety and tolerability of QLS-111 0.015% compared to active control (Timolol).

Secondary objective is to evaluate the ocular hypotensive efficacy of QLS-111 0.015% with once daily evening (QPM) and twice daily (BID) dosing versus Timolol with QPM dosing.

02

Conditions studied

  • Normal Tension Glaucoma (NTG)
  • Low-Tension Glaucoma, Bilateral
  • Low-Tension Glaucoma, Unspecified Eye
  • Glaucoma

Keywords

  • NTG
  • Qlaris
  • intraocular pressure (IOP)
  • Glaucoma
  • Nightingale
  • low-tension glaucoma
03

In context

Low Tension Glaucoma

65 studies on the registry are indexed under Low Tension Glaucoma; 9 are open to participants now.

This study's enrollment of 37 is below the median of 42 across 32 interventional studies indexed under Low Tension Glaucoma.

Browse Low Tension Glaucoma studies →

Lead sponsor

Qlaris Bio, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 30 years or older
  • Able to provide written acknowledgement of giving
  • Best corrected visual acuity (BCVA) 20/200 or better
  • NTG in both eyes with untreated IOP \<21 mmHg at Visit 2 and morning assessment of Visit 3; IOP at morning assessment on Visits 2 and 3 doesn't differ more than 2 mmHg; has open iridocorneal angles, historic IOP \<22 mmHg in either eye

Exclusion criteria

Exclusion Criteria:

  • History of angle closure glaucoma, narrow or occludable angle on gonioscope
  • All secondary glaucomas
  • Severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications
  • Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1.5 years from study)
  • Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye
  • Use of other ophthalmic concomitant medications during the study
  • Refractive surgery
  • Uncontrolled hypertension or hypotension
  • Significant systemic or psychiatric disease
  • Participation in other trial 30 days prior to screening or previous enrollment and treatment with Qlaris investigational product
  • Pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    QLS-111 ophthalmic solution

    Qlaris' investigational product, QLS-111 ophthalmic solution, 0.15%, provided in single use vials, masked, and PF.

    Drug: QLS-111 ophthalmic solution (0.015%)

  • Active comparator
    Timolol maleate PF 0.5% Ophthalmic Solution

    Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) provided in single use vials, masked.

    Drug: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)

Interventions

  • QLS-111 ophthalmic solution 0.015% applied QPM OU for 7 days followed by BID dosing OU for 7 days, to constitute a 14-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

    Also known as: QLS-111

  • Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) with BID dosing OU will be administered up to 14 days. All IP for this study will be supplied masked in PF single use vials.

    Also known as: Timolol

06

What researchers measure

Primary outcomes

  1. Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs)

    Ocular safety and tolerability: (AEs)

    Time frame: 14 days

  2. Clinically significant change in visual acuity

    Ocular safety and tolerability: visual acuity

    Time frame: 14 days

  3. Clinically significant change in findings on slit lamp exam

    Ocular safety and tolerability: dilated biomicroscopy of eye to observe clinically significant changes from baseline

    Time frame: 14 days

  4. Clinically significant change in findings on fundus exam

    Ocular safety and tolerability: dilated ophthalmoscopy to observe clinically significant changes from baseline in posterior segment of eye

    Time frame: 14 days

  5. Incidence of systemic TEAEs

    Systemic safety and tolerability: AEs

    Time frame: 14 days

  6. Clinically significant changes in blood pressure (BP)

    Systemic safety and tolerability: vital sign, measuring systolic and diastolic blood pressure

    Time frame: 14 days

  7. Clinically significant changes in heart rate (HR)

    Systemic safety and tolerability: vital signs

    Time frame: 14 days

Secondary outcomes

  1. Change from baseline (CFB) of diurnal intraocular pressure (IOP) in the study eye

    Ocular hypotensive efficacy: diurnal IOP CFB

    Time frame: 14 days

  2. CFB in IOP at various timepoints in the study eye

    Ocular hypotensive efficacy: IOP CFB for multiple timepoints throughout the day

    Time frame: 14 days

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 3080, South Korea
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Feb 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Sep 8, 2023
StartActual
Aug 13, 2025
Primary completionActual
Feb 23, 2026
CompletionActual
Mar 23, 2026
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06030193
Lead sponsor
Qlaris Bio, Inc.
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Aug 13, 2025
Primary completion
Feb 23, 2026
Completion
Mar 23, 2026
Last update
Apr 3, 2026

Study contacts

Lisa Brandano
study director · Qlaris Bio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLS-111

Start the discussion